On May 19, 2025 Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), reported its partnership with Hualong Biological, an innovator in novel cancer therapeutics (Press release, Henan Hualong Biotechnology, MAY 19, 2025, View Source [SID1234653235]). Porton Advanced will provide end-to-end CDMO services for Hualong’s Multi-Activated T Cell (MATC) therapy, from process optimization to regulatory submission, accelerating its development progress.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Hualong Biological ‘s research team has established a strong clinical foundation for its MATC platform through multiple investigator-initiated trials (IITs), demonstrating significant therapeutic benefits across various solid tumor indications. Porton Advanced will leverage its industry-leading process development platforms, GMP manufacturing capabilities, and proven regulatory expertise to optimize the MATC therapy’s CMC strategy and facilitate its transition from research to clinical development.
Mingguang Huang, Chairman of Hualong Biological, commented: "We are delighted to partner with Porton Advanced. Their comprehensive CDMO technical expertise and regulatory experience in cell therapy will significantly enhance our MATC program’s development efficiency and IND preparation timeline. Together, we’re committed to advancing this innovative therapy into clinical trials to benefit patients worldwide."
Andrew Chen, CFO of Porton Advanced, stated: "Collaborating with Hualong Biological marks a strategic expansion of our CDMO services in cell therapy. We are honored to provide regulatory-compliant, high-quality MATC CMC services to support their IND application. Porton Advanced is committed to supporting partners through our integrated technology platform and regulatory experience to bring cutting-edge therapies to patients faster."